Which blood thinner is safer for clots? small study aims to find out
NCT ID NCT02559856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two common blood thinners, rivaroxaban and apixaban, in 72 adults with newly diagnosed blood clots in the legs or lungs. The main goal was to see if a larger trial is possible by checking how many patients could join and complete follow-ups. Researchers also tracked bleeding events and clot recurrences to assess safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2, Canada
-
Hôtel-Dieu de Sherbrooke
Sherbrooke, Quebec, J1G 2E8, Canada
-
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6, Canada
-
University of Alberta
Edmonton, Alberta, T6G 2G3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could tailored blood thinner dosing prevent strokes in chinese patients?
- Could a simple aspirin pill replace daily shots to prevent postpartum blood clots?
- Simple 5-Step nursing plan could slash deadly clot risk after hip surgery
- Timing of blood thinners after childbirth bleeding may prevent clots without causing more harm
- Shorter blood thinner course after birth may be just as safe
- New scan may predict dangerous clot return in lung patients